Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS)

Steven R Feldman, Morten Præstegaard, Arne H Andreasen, Johan Selmer, Tove Holm-Larsen, Steven R Feldman, Morten Præstegaard, Arne H Andreasen, Johan Selmer, Tove Holm-Larsen

Abstract

Introduction: Adherence to topical treatments for psoriasis is reported to be poor. One key contributing factor is the inconvenience associated with formulations that may be greasy, time consuming to apply, and slow to absorb. There is a paucity of patient-reported outcome measures that evaluate psoriasis patients' perceptions of treatment convenience. The Psoriasis Treatment Convenience Scale (PTCS) was therefore developed and validated.

Methods: Following a literature review of issues relating to convenience of topical treatments, important items were identified and a draft version of the PTCS was developed and underwent content validity testing (n = 20). The revised scale was included in a clinical trial of topical therapy (n = 794; NCT03308799), and psychometric testing was performed.

Results: The final questionnaire included five core items and one overall satisfaction question. In psychometric testing, the scale demonstrated stability across trial population, and good validity, reliability, and sensitivity.

Conclusion: The PTCS is a new, reliable, sensitive, validated tool for the assessment of patient-reported treatment convenience. Use of the PTCS will facilitate evaluation of convenience as part of the clinical development of topical therapies, and thus may help to improve patient adherence and, therefore, treatment outcomes.

Keywords: Convenience; Patient-reported outcome measures; Psoriasis; Treatment adherence and compliance.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
The PTCS scale and its domains

References

    1. Hendriks AGM, Keijsers RRMC, de Jong EMGJ, Seyger MMB, van de Kerkhof PCM. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(8):931–951. doi: 10.1111/jdv.12058.
    1. Lebwohl M. Psoriasis. Ann Intern Med. 2018;168(7):Itc49–itc64. doi: 10.7326/AITC201804030.
    1. Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatolog Treat. 2017;28(5):374–383. doi: 10.1080/09546634.2016.1254331.
    1. Saeki H, Imafuku S, Abe M, et al. Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients. J Dermatol. 2015;42(4):367–372. doi: 10.1111/1346-8138.12804.
    1. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–216. doi: 10.1016/j.jaad.2004.01.052.
    1. Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764. doi: 10.1111/bjd.15085.
    1. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–67. doi: 10.1111/j.1468-3083.2012.04525.x.
    1. Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol. 2017;176(3):667–676. doi: 10.1111/bjd.15086.
    1. Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6. doi: 10.1111/j.1468-3083.2005.01329.x.
    1. Svendsen MT, Andersen KE, Andersen F, Hansen J, Pottegård A, Johannessen H. Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids. Psoriasis (Auckl) 2016;6:113–119.
    1. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–69. doi: 10.3109/09546634.2011.607425.
    1. U.S. Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Food and Drug Administration.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–977. doi: 10.1016/j.jval.2011.06.014.
    1. Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–988. doi: 10.1016/j.jval.2011.06.013.
    1. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
    1. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. doi: 10.2147/PPA.S117006.
    1. Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review. J Dermatolog Treat. 2017;28(1):32–39. doi: 10.1080/09546634.2016.1178375.
    1. Radtke MA, Spehr C, Reich K, Rustenbach SJ, Feuerhahn J, Augustin M. Treatment satisfaction in psoriasis: development and use of the psoSat patient questionnaire in a cross-sectional study. Dermatology (Basel) 2016;232(3):334–343. doi: 10.1159/000444635.
    1. Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2021;84(2):432–470.
    1. Elmets CA, Korman NJ, Prater EF, Hariharan, Menter A, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020.
    1. Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A Phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420–425. doi: 10.36849/JDD.5653.
    1. Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319. doi: 10.1007/s00403-018-1808-x.
    1. Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253–2263. doi: 10.1111/jdv.15913.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere